MedTrace Logo

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

NCT04062032 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-02-18

No results posted yet for this study

Summary

This is an open label phase II pilot study assessing the metabolomic and inflammatory effects of oral aspirin (ASA) in human subjects at risk for melanoma.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

Aspirin 81 mg

ASA 81mg taken daily

DRUG

Aspirin 325mg

ASA 325mg taken daily

Sponsors & Collaborators

Principal Investigators

  • Douglas Grossman, MD · Huntsman Cancer Institute/ University of Utah

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-27
Primary Completion
2019-02-27
Completion
2019-02-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04062032 on ClinicalTrials.gov